BeOne Medicines: Lymphoma trials

The registry lists 13 Lymphoma studies with BeOne Medicines as lead sponsor. 0 are open to participants now and 11 have results posted.

Phase 1 4Phase 2 10Phase 3 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study of Sonrotoclax (BGB-11417) Monotherapy in Participants With Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT05471843Phase 1/2Results posted
• Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or RituximabCompletedNCT05267054Phase 1/2Results posted
• Zanubrutinib, in Combination With Lenalidomide, With or Without Rituximab in Participants With Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT04436107Phase 1Results posted
• Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone LymphomaCompletedNCT03846427Phase 2Results posted
• A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic LeukemiaCompletedNCT03734016Phase 3Results posted
• BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)CompletedNCT03520920Phase 2Results posted
• A Study of Tislelizumab as Monotherapy in Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT03209973Phase 2Results posted
• Study to Evaluate Efficacy and Safety of BGB-3111 in Participants With Relapsed or Refractory Mantle Cell Lymphoma (MCL)CompletedNCT03206970Phase 2Results posted
• Efficacy and Safety of Zanubrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT03206918Phase 2Results posted
• A Study to Investigate Zanubrutinib in Chinese Participants With B-cell LymphomaCompletedNCT03189524Phase 1Results posted
• Study of BTK Inhibitor Zanubrutinib in Participants With Relapsed/Refractory Non-GCB Type Diffuse Large B Cell LymphomaCompletedNCT03145064Phase 2Results posted
• A Study to Investigate Efficacy and Safety of BCL2 Inhibitor Sonrotoclax as Monotherapy and in Combination With Zanubrutinib in Adults With Waldenström MacroglobulinemiaActive, not recruitingNCT05952037Phase 2
• Study of BGB-11417 in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05479994Phase 2